AKT1 and breast cancer: Two of the four breast cancer cell lines with SCRIB, VANGL2 and NOS1AP concomitant amplification in the CCLE collection display sensitivity to porcupine inhibitors, and one of them also shows sensitivity to drugs affecting the PI3K/AKT/mTOR pathway.